Folate-mediated 1-carbon metabolism is a network of interconnected metabolic pathways necessary for the synthesis of purine nucleotides, thymidylate and the remethylation of homocysteine to methionine. Disruptions in this pathway influence both DNA synthesis and stability and chromatin methylation, and result from nutritional deficiencies and common gene variants. The mechanisms underlying folate-associated pathologies and developmental anomalies have yet to be established. This review focuses on the relationships among folate-mediated 1-carbon metabolism, chromatin methylation and human disease, and the role of gene-nutrient interactions in modifying epigenetic processes.

Epigenetics refers to the inheritance and/or self-propagation of gene expression potential that is independent of the primary DNA sequence [1,2]. Epigenetics includes biological processes that are hardwired and mostly genetically determined, such as genomic imprinting [3], whereby genes exhibit parent-of-origin-specific allelic expression [4]. The term also includes more plastic processes including chromatin modifications resulting from metabolic, nutritional and other environmental queues [5]. Environmentally responsive chromatin modifications can be reversible, transient and enable adaptation, or in other cases persist throughout the lifetime of the organism. The latter is referred to as metabolic imprinting, and includes the influence of maternal nutrition during gestation and the suckling period on chromatin modifications and gene expression profiles that influence lifelong risk of chronic disease [6].

Chromatin methylation, which includes methylation of cytosine bases within DNA CpG islands [7] and methylation of histones on lysine and arginine residues [8], directly affects the activity and function of DNA binding proteins, regulates gene expression and can influence genome stability. Histone and DNA methylation are linked and coordinately regulated [9], can affect gene expression patterns, and are a primary molecular mechanism associated with epigenetic signatures and inheritance [10].

DNA and histone protein methylation are linked by their common dependence upon S-adenosylmethionine (AdoMet) as a methyl donor. All DNA and histone methyltransferases require this cofactor for both cytosine as well as lysine and arginine histone modifications [11,12]. AdoMet synthesis occurs through a metabolic network known as folate-mediated 1-carbon metabolism, which requires folate, vitamin B12 and other water-soluble B vitamins [13]. The dependency of cellular methylation reactions on AdoMet synthesis and availability enables the cell to sense cellular metabolism and nutritional state, and respond and adapt by altering genome-wide expression patterns [14]. This review focuses on the genetic and nutritional factors that influence the synthesis and accumulation of AdoMet, and its influence on chromatin methylation and pathologies associated with altered folate-mediated 1-carbon metabolism (fig. 1).

Fig. 1

Folate-dependent homocysteine remethylation and its interaction with AdoMet-dependent transmethylation reactions. One-carbon metabolism in the cytoplasm generates folate-activated 1-carbon units for remethylation of homocysteine to methionine. One carbon metabolism in the mitochondria generates formate for 1-carbon metabolism in the cytoplasm. The 1-carbon unit is shown in bold. BHMT = Betaine-homocysteine methyltransferase; X = a substrate that serves as a methyl group acceptor.

Fig. 1

Folate-dependent homocysteine remethylation and its interaction with AdoMet-dependent transmethylation reactions. One-carbon metabolism in the cytoplasm generates folate-activated 1-carbon units for remethylation of homocysteine to methionine. One carbon metabolism in the mitochondria generates formate for 1-carbon metabolism in the cytoplasm. The 1-carbon unit is shown in bold. BHMT = Betaine-homocysteine methyltransferase; X = a substrate that serves as a methyl group acceptor.

Close modal

Folate-mediated 1-carbon metabolism is a metabolic network present in the cytoplasm, mitochondria and nucleus of cells and functions to generate and transfer 1-carbons for the de novo synthesis of purines, thymidylate and methionine [13]. These biosynthetic pathways all utilize tetrahydrofolate polyglutamates (THF) as cofactors. THF is present in cells as family of 1-carbon substituted cofactors that carry and chemically activate single carbons for 1-carbon transfer reactions. Because folate is a vitamin, it is acquired from the diet from either natural food or enriched grain products and dietary supplements which contain a synthetic form of the vitamin referred to as folic acid [15].

One-carbon metabolism in mitochondria utilizes THF cofactors to generate the 1-carbon unit formate from the amino acids serine, glycine, and from sarcosine and dimethylglycine which are derived from choline degradation [13,16]. Once generated, formate is transported into the cytoplasm where it condenses with THF in an ATP-dependent reaction to form 10-formyl-THF (FTHF; fig. 1). Formate is the primary source of 1-carbons for de novo purine biosynthesis and for homocysteine remethylation to methionine, and therefore formate generation is essential for AdoMet-dependent methylation reactions, including chromatin methylation [17,18]. The de novo synthesis of thymidylate from uridylate occurs in both the mitochondria and nucleus [19].

The remethylation of homocysteine to methionine and subsequent conversion of methionine to AdoMet occurs exclusively in the cytoplasm [20] (fig. 1). Mammalian cells contain numerous AdoMet-dependent methyltransferases involved in many cellular processes including chromatin remodeling, regulatory functions including gene transcription [21], protein localization [22], and the biosynthesis and catabolism of small molecules including neurotransmitters [23]. These reactions occur in the cytoplasm, nucleus and mitochondria, and generate S-adenosylhomocysteine (AdoHcy), which is the product of AdoMet-dependent transmethylation reactions. AdoHcy is hydrolyzed to adenosine and homocysteine to complete the homocysteine remethylation cycle in the cytoplasm (fig. 1).

One-carbon metabolism is highly sensitive to vitamin deficiency [17], and its impairment impacts each of the folate-dependent pathways resulting in decreased rates of purine and thymidylate synthesis, elevated levels of homocysteine and AdoHcy and depleted levels of AdoMet [24]. These metabolic disruptions affect DNA synthesis and stability and impair cellular methylation reactions [24,25]. Vitamin B12 deficiency can also disrupt 1-carbon metabolism. Methionine synthase (MTR), which catalyzes the remethylation of homocysteine to methionine, is vitamin B12 dependent [26]. It has been estimated that 38% of older adults may exhibit mild vitamin B12 deficiency [27]. Both folate and vitamin B12 deficiency elevate plasma homocysteine and AdoHcy [27], and homocysteine is a biomarker for folate and vitamin B12 deficiency [28].

Population studies and randomized clinical trials implicate impaired 1-carbon metabolism in several pathologies and developmental anomalies, e.g. neural tube defects [29,30], cardiovascular disease [31,32,33] and cancer [34,35,36,37,38]. Elevated plasma homocysteine, resulting from folate and/or vitamin B12 deficiency, is a risk factor for certain cancers [39], cardiovascular disease [40], neural tube defects [41], and Alzheimer’s disease [42]. These folate-related pathologies are complex traits resulting from deleterious gene-environment interactions [14]. Although nutritional deficiencies in folate and vitamin B12 can impair 1-carbon metabolism, the degree of the metabolic impairment and its relationship to pathology depends on the genetic background of the individual. Many common, penetrant genetic mutations and polymorphisms have been identified in 1-carbon metabolism that are associated with pathology and interact with and/or can cause nutritional deficiencies [29,43,44,45]. The molecular mechanisms and causal pathways underlying the gene-nutrient interactions that contribute to the initiation and/or progression of folate-associated pathologies have yet to be established, but are assumed to result from impairments in DNA synthesis and repair, and/or changes in chromatin methylation that alter genome expression and stability [24].

The ratio of AdoMet to AdoHcy levels in the cell is often referred to as the methylation potential [46]. AdoMet and AdoHcy both affect the activity of AdoMet-dependent methyltransferases. AdoMet serves as the substrate for transmethylation reactions including DNA and histone methyltransferases, whereas the product, AdoHcy, binds tightly to these enzymes and inhibits their activity through product inhibition and therefore is a physiologically relevant inhibitor of chromatin methylation. AdoHcy accumulates in cells when homocysteine remethylation to methionine is inhibited, because homocysteine is in equilibrium with AdoHcy (fig. 1). Therefore, metabolic disruptions in 1-carbon metabolism that impair homocysteine remethylation are sensed by the genome through changes in chromatin methylation, and elicit alterations in gene expression [47].

Changes in the AdoMet/AdoHcy ratio influence the cellular activity of DNA and histone methyltransferases, and different regions of DNA may be more sensitive than others to changes in the cellular methylation potential [48]. Subcutaneous methionine treatment (5 mmol/kg twice a day for 3 days) induces GAD67 promoter hypermethylation in mice through elevations in AdoMet levels [49]. In human lymphocytes, AdoHcy is a more important determinant of cellular methylation capacity and global DNA methylation levels compared to AdoMet [50]. In mice with elevated homocysteine, AdoHcy but not AdoMet predicts global DNA hypomethylation [51]. Other studies demonstrated that mice maintained on a folate-deficient diet (<0.05 ppm folic acid) for 32 weeks exhibited elevated serum homocysteine and global DNA hypomethylation in splenocytes (reduced 9.1%) and colonic epithelial cells (reduced 7.2%), without changes in allele-specific methylation at the mouse B1 element, H19 or Oct4 loci [25]. Endothelial cells exposed to homocysteine exhibited 30% reduced DNA methyltransferase 1 (DNMT1) activity without changes in DMNT1 protein levels, and reduced CpG methylation of the cyclin A promoter, leading to depressed cyclin A transcription. These studies demonstrate that homocysteine-induced elevations in AdoHcy repress DNMT1 activity and chromatin methylation [52].

AdoHcy elevations have also been demonstrated to affect the expression of genetically imprinted genes. Elevations in plasma homocysteine at levels observed in patients with homocystinuria resulted in DNA CpG hypomethylation and biallelic expression of H19 and other genomically imprinted genes. Folic acid administration, in the form of 15 mg oral methyl-THF a day for 8 weeks, corrected the DNA hypomethylation and restored monoallelic gene expression patterns [53]. Diet-induced changes in the cellular methylation potential also influence imprinted gene expression in animal models. Mice lacking dietary choline and methionine exhibited elevated Igf2 and H19 expression in the prostate without changes in promoter methylation or imprinting, but did exhibit lower levels of repressive histone modifications (dimethyl-H3K9). These effects were reversible by feeding mice a nutrient-sufficient diet [54]. In non-small cell lung cancers, folate levels correlated with global methylation when LINE-1 methylation is used as a surrogate, as well as allelic-specific methylation at the promoters of CDH13, RUNX3, but not MYOD1, RASSF1P16, APC, and RARB. Therefore, folate levels influence both global and allele-specific methylation in transformed cells [55]. Vitamin B12 deficiency, induced in gastrectomized rats which have reduced capacity to absorb vitamin B12, also causes elevated plasma homocysteine and DNA hypomethylation in rodents [56]. However, the relationship between diet and DNA methylation may be most pronounced in nutrient deficiency, in cancers and in severe inborn errors of metabolism that elevate homocysteine. Folate nutrition and global DNA CpG methylation do not always correlate; folate supplementation of human subjects at 1 mg/day did not alter LINE-1 methylation density, which is a proxy for DNA global methylation, in normal colonic mucosa cells [57].

Changes in DNMT1 expression correlate with CpG methylation levels in nuclear DNA in tissues and transgenic animals [58], indicating that methyltransferase levels, like changes in the AdoMet/AdoHcy ratio, affect cellular methylation capacity. DNMT1 ensures that DNA methylation patterns are reestablished during DNA replication and that global DNA methylation levels are maintained.

One-carbon metabolism also regulates the expression of methyltransferases, in addition to maintaining the AdoMet/AdoHcy ratio. DMNT1 levels are increased in choline-deficient embryos leading to increased global DNA methylation, including Igf2 methylation. Choline degradation is a source of formate from mitochondrial 1-carbon metabolism, and provides an alternative pathway for homocysteine remethylation independent of folate metabolism through the enzyme betaine-homocysteine methyltransferase [59]. Choline deficiency induces hypomethylation of the Dnmt1 promoter and increased Dnmt1 expression, indicating that Dnmt1 promoter hypomethylation is a compensatory mechanism that maintains methylation capacity when the AdoMet/AdoHcy ratio decreases [60]. mRNA levels of Dnmt3a, a de novo DNA methyltransferase, also inversely correlate with maternal choline intake [60].

Genetic variation in the genes that encode the enzymes that constitute folate-mediated 1-carbon metabolism is associated with changes in cellular metabolism, genome methylation and risk for human pathologies. This section reviews common genetic variants in this metabolic network and their impact on 1-carbon metabolism, epigenetic processes and human disease.

Methylenetetrahydrofolate Dehydrogenase 1

The mammalian MTHFD1 gene encodes C1-THF synthase, a trifunctional enzyme that contains FTHF synthetase (FTHFS) activity on the C-terminal domain, and 5,10-methenyl-THF cyclohydrolase (MTHFC) and dehydrogenase (MTHFD) activities on the N-terminal domain [61,62] (fig. 1). FTHFS functions as a formate-activating enzyme by catalyzing the ATP-dependent conversion of THF and formate to FTHF, ADP, and inorganic phosphate [16]. FTHF is used as cofactor for purine biosynthesis [63], or the 1-carbon can be reduced by MTHFC/MTHFD for use in the biosynthesis of thymidylate and methionine (fig. 1). MTHFC catalyzes the reversible interconversion of FTHF and 5,10-methenyl-THF, whereas MTHFD catalyzes the NADPH-dependent and reversible reduction of 5,10-methenyl-THF to 5,10-methylene-THF. Disruption of a single Mthfd1 allele in mice lowers hepatic AdoMet levels, consistent with formate serving as a source of 1-carbons for cellular methylation reactions [64] (fig. 1).

A common single nucleotide variant in human Mthfd1, G1958A, results in the substitution of glutamine for arginine at position 653 in the 10-FTHFS domain of MTHFD1. The variant enzyme is thermolabile with 25% reduced activity in cultured cells [65]. In humans, the R653Q variant does not influence levels of homocysteine, plasma folate or red blood cell folate [66], but was found to increase a mother’s risk of having a child with a neural tube defect in several populations [66,67,68], to increase risk for intrauterine growth restriction [69], to increase risk for congenital heart defects [65], and to increase risk for non-Hodgkin’s lymphoma [70]. This polymorphism is also a maternal risk factor for severe placental abruption and unexplained second trimester loss [71,72], and has been demonstrated to be a maternal and fetal risk factor for cleft lip and cleft palate in an Irish population [73], but not in an Italian population [74]. There is also a common variant in the MTHFD/MTHFC domain (R134K), but the functional significance of the variant domain is not known. It has been associated with a significant increase in the risk for postmenopausal breast cancer [75].

FTHF Dehydrogenase (ALDH1L1)

ALDH1L1 catalyzes the irreversible and NADP+-dependent oxidation of FTHF to THF and CO2 [76,77]. It is one of the most abundant folate enzymes in the liver and plays several roles in regulating folate metabolism, including the removal of excess FTHF in the form of CO2. ALDH1L1 has been shown to regulate cellular concentrations of FTHF and the homocysteine remethylation cycle in cultured neuroblastoma cells [78] by limiting the supply of folate-activated 1-carbon units. Interestingly, ALDH1L1 gene expression is epigenetically silenced in cancers [79]. Two ALDH1L1 gene variants have been shown to alter the risk of developing postmenopausal breast cancer. The variant [rs2276731 (T/C)] is associated with an increased risk, while [rs2002287 (T/C)] is associated with a decreased risk. Both single nucleotide polymorphisms are intronic, and may exist in linkage disequilibrium with coding variants including V812I, G481S, or F330V [75].

5,10-Methylene-THF Reductase

Methylene-THF reductase (MTHFR) is a flavoprotein that catalyzes the NADPH-dependent reduction in 5,10-methylene-THF to 5-methyl-THF, which is an essential folate cofactor for the remethylation of homocysteine to methionine (fig. 1). The MTHFR reaction is irreversible in vivo and thereby commits folate cofactors to the homocysteine remethylation pathway [16,80]. MTHFR activity is inhibited by AdoMet, providing feedback inhibition and limiting AdoMet synthesis and accumulation [81].

MTFHR is expressed ubiquitously, with the highest mRNA levels observed in the testis where DNA methylation is critical for germ cell maturation and genomic imprinting [82]. Mild MTHFR deficiency, defined as 35–45% residual activity, is the most common inborn error of folate metabolism and affects 5–20% of North Americans and Europeans [83]. The most common cause is a C to T substitution at nucleotide position 677, which results in the amino acid change (A222V) in the catalytic domain of the protein [84]. The C677T variant does not exhibit altered kinetic properties compared to the more common allele, but rather exhibits enhanced loss of the FAD cofactor [83,85,86] creating a thermolabile protein [87]. The C677T variant is associated with mild hyperhomocysteinemia, especially in those with low folate concentrations [88], and lower plasma and red cell folate levels [89,90]. The C677T variant has been demonstrated to effect the cellular methylation potential and is associated with DNA hypomethylation in lymphocytes [91] and increased tumor suppressor gene CDKN2A promoter methylation in colon cancer [92].

The C677T MTHFR variant has been shown to modify risk for several clinical outcomes, especially outcomes related to reproduction and cancer, as well as chronic disease. The variant has been shown to be associated with an increased risk for cardiovascular disease [93,94,95], neural tube defects [96,97,98], cleft lip and palate [41,99], thrombosis [100,101,102] and schizophrenia [103,104,105,106]. It has also been shown to be protective against several types of cancers, including acute lymphoblastic leukemia [107], childhood acute leukemia [108], and colorectal cancer [109,110]. It is not known if the association of the MTHFR C677T variant with pathology results from its effect on the homocysteine remethylation pathway and cellular methylation, or from its effect on lowering cellular folate levels.

Another common coding MTHFR single nucleotide polymorphism, A1298C (E429A), exists in strong linkage disequilibrium with C677T [111]. Unlike C677T which affects the active site of the protein, A1298C is located in the regulatory domain of the protein and is catalytically indistinguishable from the wild-type MTHFR [86]. The A1298C polymorphism is associated with increased red cell folate levels and does not affect homocysteine levels [90]. This polymorphism was shown to be associated with a decreased risk for acute lymphoblastic leukemia [107] and childhood acute leukemia [108].

Methionine Synthase

MTR is a cobalamin (vitamin B12)-dependent enzyme that catalyzes the 5-methyl-THF-dependent remethylation of homocysteine to methionine (fig. 1). MTR activity is essential to supply methionine for AdoMet synthesis and the transmethylation reactions (fig. 1), and to prevent the accumulation of homocysteine and its conversion to AdoHcy. MTR is an essential enzyme in mice; mice lacking MTR exhibit embryonic lethality [112]. Although MTR activity is redundant with betaine-homocysteine methyltransferase which can also remethylate homocysteine to form methionine, its expression is limited to the liver and kidney, whereas methionine synthetase displays ubiquitous expression [113].

Inborn errors of metabolism associated with MTR, including the P1173L mutation, result in an autosomal recessive disease characterized by homocysteinemia, homocystinuria, hypomethioninemia, megaloblastic anemia, neural dysfunction, and mental retardation [114]. The common MTR polymorphic variant, A2756G, which affects the domain involved in methylation and activation of the vitamin B12 cofactor [115], is associated with more subtle clinical outcomes; including decreased plasma homocysteine levels [116] and aberrant methylation in patients with colorectal, breast, and lung tumors [117], and is a risk factor for systemic lupus erythematosus [118], bipolar disorder, schizophrenia [119], spina bifida [120], orofacial clefts [121], nonsyndromic cleft lip and palate [122] and Down’s syndrome [123]. This variant was also shown to reduce MLH1 promoter hypermethylation in colorectal cancer [124].

Glycine N-Methyltransferase

Glycine N-methyltransferase (GNMT) is a methyltransferase that catalyzes the AdoMet-dependent methylation of glycine to sarcosine. The primary function of this reaction is to regulate and buffer the AdoMet/AdoHyc ratio and prevent AdoMet accumulation. Mice lacking GNMT exhibit fatty liver with a 36-fold elevation in AdoMet concentrations and a 100-fold increase in the AdoMet/AdoHcy ratio [125]. Humans with loss-of-function GNMT mutations present with similar metabolic disruptions [125]. GNMT expression is regulated by other nutrients, including retinoic acid [126] and glucocorticoids [127]; this regulation of GNMT expression provides a mechanism whereby nutrients unrelated to 1-carbon metabolism signal influence chromatin methylation and epigenetic processes [12]. The GNMT C1289T variant was shown to be associated with elevated plasma total homocysteine concentrations in women with the MTHFR C677T genotype [128].

One-Carbon Metabolism in Mitochondria

Mitochondria play an important role in generating formate for AdoMet synthesis in the cytoplasm, but our understanding of the pathway and its regulation is incomplete, including its role in folate-associated pathologies and cellular methylation reactions. A connection between mitochondrial 1-carbon metabolism and homocysteine has been established in patients with nonketotic hyperglycinemia, an autosomal recessive inborn error of metabolism caused by mutations in the P-protein or T-protein of the glycine cleavage system [129]. This system accounts for nearly 40% of overall glycine flux in humans and the formate produced from glycine catabolism makes major contributions to 1-carbon flux through cytoplasmic 1-carbon metabolism [130]. Mutations in the glycine cleavage system are associated with elevated homocysteine levels in cerebrospinal fluid, severe mental retardation, seizures, apnea, and hypotonia, but their impact on cellular methylation has yet to be established [131].

Folate-mediated 1-carbon metabolism is a conduit that links cellular metabolism to the epigenetic machinery through the common molecule, AdoMet. There is strong evidence that changes in the cellular methylation potential (AdoMet/AdoHcy ratio), induced by changes in cellular metabolism, can influence the activity of both DNA and histone methyltransferases and the expression of DNA methyltransferases, and thereby alter chromatin methylation patterns. These changes in chromatin methylation can be global and/or allele specific. It remains to be established how changes in the cellular methylation potential can induce allele-specific alterations in genome methylation, including the mechanisms underlying the targeting of specific alleles. Likewise, the establishment of pathways that link B-vitamin nutrition, cellular methylation and downstream effects on gene expression is needed to elucidate mechanisms underlying B-vitamin-associated pathologies. Finally, understanding the relative contributions of genetic variation and environment (including nutrition) to epigenetic processes is essential to the design of nutritional and/or pharmaceutical approaches for the prevention and management of chronic disease.

This work was supported by PHS DK58144 to P.J.S

The author has no conflict of interest.

1.
Bird A: Perceptions of epigenetics. Nature 2007;447:396–398.
2.
Ptashne M: On the use of the word ‘epigenetic’. Curr Biol 2007;17:R233–R236.
3.
Reik W, Walter J: Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001;2:21–32.
4.
Koerner MV, Barlow DP: Genomic imprinting – an epigenetic gene-regulatory model. Curr Opin Genet Dev 2010;20:164–170.
5.
Kim KC, Friso S, Choi SW: DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem 2009;20:917–926.
6.
Waterland RA, Garza C: Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999;69:179–197.
7.
Feil R: Epigenetics: ready for the marks. Nature 2009;461:359–360.
8.
Mosammaparast N, Shi Y: Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 2010;79:155–179.
9.
Ciccone DN, Su H, Hevi S, Gay F, Lei H, et al: KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 2009;461:415–418.
10.
Skinner MK: Environmental epigenetic transgenerational inheritance and somatic epigenetic mitotic stability. Epigenetics 2011;6:838–842.
11.
Loenen WA: S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans 2006;34:330–333.
12.
Luka Z, Mudd SH, Wagner C: Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem 2009;284:22507–22511.
13.
Fox JT, Stover PJ: Folate-mediated one-carbon metabolism. Vitam Horm 2008;79:1–44.
14.
Stover PJ, Caudill MA: Genetic and epigenetic contributions to human nutrition and health: managing genome-diet interactions. J Am Diet Assoc 2008;108:1480–1487.
15.
Yang Q, Cogswell ME, Hamner HC, Carriquiry A, Bailey LB, et al: Folic acid source, usual intake, and folate and vitamin B-12 status in US adults: National Health and Nutrition Examination Survey (NHANES) 2003–2006. Am J Clin Nutr 2009;91:64–72.
16.
Appling DR: Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 1991;5:2645–2651.
17.
Herbig K, Chiang EP, Lee LR, Hills J, Shane B, et al: Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J Biol Chem 2002;277:38381–38389.
18.
Davis SR, Stacpoole PW, Williamson J, Kick LS, Quinlivan EP, et al: Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. Am J Physiol Endocrinol Metab 2004;286:E272–E279.
19.
Anderson DD, Stover PJ: SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PLoS One 2009;4:e5839.
20.
Martinov MV, Vitvitsky VM, Banerjee R, Ataullakhanov FI: The logic of the hepatic methionine metabolic cycle. Biochim Biophys Acta 2010;1804:89–96.
21.
Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007;213:384–390.
22.
Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, et al: Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 2003;100:6529–6534.
23.
Stead LM, Jacobs RL, Brosnan ME, Brosnan JT: Methylation demand and homocysteine metabolism. Adv Enzyme Regul 2004;44:321–333.
24.
Stover PJ: Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004;62:S3–S12, discussion S13.
25.
Linhart HG, Troen A, Bell GW, Cantu E, Chao WH, et al: Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology 2009;136:227.e3–235.e3.
26.
Baik HW, Russell RM: Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999;19:357–377.
27.
Hoey L, Strain JJ, McNulty H: Studies of biomarker responses to intervention with vitamin B-12: a systematic review of randomized controlled trials. Am J Clin Nutr 2009;89:1981S–1996S.
28.
Selhub J, Jacques PF, Dallal G, Choumenkovitch S, Rogers G: The use of blood concentrations of vitamins and their respective functional indicators to define folate and vitamin B12 status. Food Nutr Bull 2008;29:S67–S73.
29.
van der Put NM, Blom HJ: Neural tube defects and a disturbed folate dependent homocysteine metabolism. Eur J Obstet Gynecol Reprod Biol 2000;92:57–61.
30.
Scott JM: Evidence of folic acid and folate in the prevention of neural tube defects. Bibl Nutr Dieta 2001;192–195.
31.
Ueland PM, Refsum H, Beresford SA, Vollset SE: The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324–332.
32.
Gerhard GT, Duell PB: Homocysteine and atherosclerosis. Curr Opin Lipidol 1999;10:417–428.
33.
Lindenbaum J, Allen RH: Clinical spectrum and diagnosis of folate deficiency; in: Bailey LB (ed): Folate in Health and Disease. New York,l Dekker, 1995.
34.
Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, et al: Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290–3295.
35.
Ames BN: DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res 2001;475:7–20.
36.
Choi SW, Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129–132.
37.
Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, et al: Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res 1995;55:1894–1901.
38.
Kim YI: Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev 1999;57:314–321.
39.
Kerr MA, Livingstone B, Bates CJ, Bradbury I, Scott JM, et al: Folate, related B vitamins, and homocysteine in childhood and adolescence: potential implications for disease risk in later life. Pediatrics 2009;123:627–635.
40.
Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31–62.
41.
Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, et al: Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149–151.
42.
Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, et al: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449–1455.
43.
Bailey LB: Folate requirements and dietary recommendations; in Bailey LB (ed): Folate in Health and Disease. New York, Dekker, 1995.
44.
McNulty H: Folate requirements for health in different population groups. Br J Biomed Sci 1995;52:110–119.
45.
Scott JM: How does folic acid prevent neural tube defects? Nat Med 1998;4:895–896.
46.
Finkelstein JD: Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med 2007;45:1694–1699.
47.
Jhaveri MS, Wagner C, Trepel JB: Impact of extracellular folate levels on global gene expression. Mol Pharmacol 2001;60:1288–1295.
48.
Waterland RA, Jirtle RL: Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 2004;20:63–68.
49.
Satta R, Maloku E, Zhubi A, Pibiri F, Hajos M, et al: Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci USA 2008;105:16356–16361.
50.
Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, et al: Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318–29323.
51.
Caudill MA, Wang JC, Melnyk S, Pogribny IP, Jernigan S, et al: Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. J Nutr 2001;131:2811–2818.
52.
Jamaluddin MD, Chen I, Yang F, Jiang X, Jan M, et al: Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007;110:3648–3655.
53.
Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, et al: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693–1699.
54.
Dobosy JR, Fu VX, Desotelle JA, Srinivasan R, Kenowski ML, et al: A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. Prostate 2008;68:1187–1195.
55.
Jin M, Kawakami K, Fukui Y, Tsukioka S, Oda M, et al: Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009;100:2325–2330.
56.
Brunaud L, Alberto JM, Ayav A, Gerard P, Namour F, et al: Vitamin B12 is a strong determinant of low methionine synthase activity and DNA hypomethylation in gastrectomized rats. Digestion 2003;68:133–140.
57.
Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, et al: Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev 2009;18:1041–1049.
58.
Kim M, Trinh BN, Long TI, Oghamian S, Laird PW: Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res 2004;32:5742–5749.
59.
Schwahn BC, Laryea MD, Chen Z, Melnyk S, Pogribny I, et al: Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J 2004;382:831–840.
60.
Kovacheva VP, Mellott TJ, Davison JM, Wagner N, Lopez-Coviella I, et al: Gestational choline deficiency causes global and Igf2 gene DNA hypermethylation by up-regulation of Dnmt1 expression. J Biol Chem 2007;282:31777–31788.
61.
Paukert JL, Straus LD, Rabinowitz JC: Formyl-methyl-methylenetetrahydrofolate synthetase-(combined). An ovine protein with multiple catalytic activities. J Biol Chem 1976;251:5104–5111.
62.
Tan LU, Drury EJ, MacKenzie RE: Methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. A multifunctional protein from porcine liver. J Biol Chem 1977;252:1117–1122.
63.
Smith GK, Mueller WT, Benkovic PA, Benkovic SJ: On the cofactor specificity of glycinamide ribonucleotide and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase from chicken liver. Biochemistry 1981;20:1241–1245.
64.
MacFarlane AJ, Perry CA, Girnary HH, Gao D, Allen RH, et al: Mthfd1 is an essential gene in mice and alters biomarkers of impaired one-carbon metabolism. J Biol Chem 2009;284:1533–1539.
65.
Christensen KE, Rohlicek CV, Andelfinger GU, Michaud J, Bigras JL, et al: The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat 2009;30:212–220.
66.
Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, et al: A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002;71:1207–1215.
67.
De Marco P, Merello E, Calevo MG, Mascelli S, Raso A, et al: Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G>A polymorphism for neural tube defect risk. J Hum Genet 2006;51:98–103.
68.
Parle-McDermott A, Kirke PN, Mills JL, Molloy AM, Cox C, et al: Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 2006;14:768–772.
69.
Furness DL, Fenech MF, Khong YT, Romero R, Dekker GA: One-carbon metabolism enzyme polymorphisms and uteroplacental insufficiency. Am J Obstet Gynecol 2008;199:276.e1–276.e8.
70.
Weiner AS, Beresina OV, Voronina EN, Voropaeva EN, Boyarskih UA, et al: Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin’s lymphoma. Leuk Res 2011;35:508–515.
71.
Parle-McDermott A, Mills JL, Kirke PN, Cox C, Signore CC, et al: MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae. Am J Med Genet A 2005;132:365–368.
72.
Parle-McDermott A, Pangilinan F, Mills JL, Signore CC, Molloy AM, et al: A polymorphism in the MTHFD1 gene increases a mother’s risk of having an unexplained second trimester pregnancy loss. Mol Hum Reprod 2005;11:477–480.
73.
Mills JL, Molloy AM, Parle-McDermott A, Troendle JF, Brody LC, et al: Folate-related gene polymorphisms as risk factors for cleft lip and cleft palate. Birth Defects Res A Clin Mol Teratol 2008;82:636–643.
74.
Palmieri A, Masiero E, Martinelli M, Scapoli L, Pezzetti F, et al: The MTHFD1 gene is not involved in cleft lip with or without palate onset among the Italian population. Ann Hum Genet 2008;72:297–299.
75.
Stevens VL, McCullough ML, Pavluck AL, Talbot JT, Feigelson HS, et al: Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev 2007;16:1140–1147.
76.
Donato H, Krupenko NI, Tsybovsky Y, Krupenko SA: 10-Formyltetrahydrofolate dehydrogenase requires a 4′-phosphopantetheine prosthetic group for catalysis. J Biol Chem 2007;282:34159–34166.
77.
Cook RJ, Lloyd RS, Wagner C: Isolation and characterization of cDNA clones for rat liver 10-formyltetrahydrofolate dehydrogenase. J Biol Chem 1991;266:4965–4973.
78.
Anguera MC, Field MS, Perry C, Ghandour H, Chiang EP, et al: Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. J Biol Chem 2006;281:18335–18342.
79.
Oleinik NV, Krupenko NI, Krupenko SA: Epigenetic silencing of ALDH1L1, a metabolic regulator of cellular proliferation, in cancers. Genes Cancer 2011;2:130–139.
80.
Wagner C: Biochemical role of folate in cellular metabolism; in Bailey LB (ed): Folate in Health and Disease. New York, Dekker, 1995, pp 23–42.
81.
Jencks DA, Mathews RG: Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem 1987;262:2485–2493.
82.
Gaughan DJ, Barbaux S, Kluijtmans LA, Whitehead AS: The human and mouse methylenetetrahydrofolate reductase (MTHFR) genes: genomic organization, mRNA structure and linkage to the CLCN6 gene. Gene 2000;257:279–289.
83.
Pejchal R, Campbell E, Guenther BD, Lennon BW, Matthews RG, et al: Structural perturbations in the Ala → Val polymorphism of methylenetetrahydrofolate reductase: how binding of folates may protect against inactivation. Biochemistry 2006;45:4808–4818.
84.
Goyette P, Rozen R: The thermolabile variant 677C→T can further reduce activity when expressed in cis with severe mutations for human methylenetetrahydrofolate reductase. Hum Mutat 2000;16:132–138.
85.
Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, et al: The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999;6:359–365.
86.
Yamada K, Chen Z, Rozen R, Matthews RG: Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 2001;98:14853–14858.
87.
Kang SS, Wong PW, Zhou JM, Sora J, Lessick M, et al: Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988;37:611–613.
88.
Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, et al: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.
89.
Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, et al: Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997;349:1591–1593.
90.
Parle-McDermott A, Mills JL, Molloy AM, Carroll N, Kirke PN, et al: The MTHFR 1298CC and 677TT genotypes have opposite associations with red cell folate levels. Mol Genet Metab 2006;88:290–294.
91.
Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, et al: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606–5611.
92.
Oyama K, Kawakami K, Maeda K, Ishiguro K, Watanabe G: The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res 2004;24:649–654.
93.
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, et al: MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023–2031.
94.
Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, et al: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35–41.
95.
Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, et al: Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032–2036.
96.
Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, et al: Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151–157.
97.
Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, et al: 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996;63:610–614.
98.
van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, et al: Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070–1071.
99.
Zhu J, Ren A, Hao L, Pei L, Liu J, et al: Variable contribution of the MTHFR C677T polymorphism to non-syndromic cleft lip and palate risk in China. Am J Med Genet A 2006;140:551–557.
100.
Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, et al: Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723–728.
101.
Quere I, Perneger TV, Zittoun J, Bellet H, Gris JC, et al: Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 2002;359:747–752.
102.
Zalavras ChG, Giotopoulou S, Dokou E, Mitsis M, Ioannou HV, et al: Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol 2002;21:268–271.
103.
Lewis SJ, Zammit S, Gunnell D, Smith GD: A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am J Med Genet B Neuropsychiatr Genet 2005;135:2–4.
104.
Muntjewerff JW, Hoogendoorn ML, Kahn RS, Sinke RJ, Den Heijer M, et al: Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am J Med Genet B Neuropsychiatr Genet 2005;135:69–72.
105.
Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M: Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006;11:143–149.
106.
Scher AI, Terwindt GM, Verschuren WM, Kruit MC, Blom HJ, et al: Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 2006;59:372–375.
107.
Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, et al: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999;96:12810–12815.
108.
Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, et al: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 2001;98:4004–4009.
109.
Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, et al: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862–4864.
110.
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, et al: Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098–1102.
111.
Stegmann K, Ziegler A, Ngo ET, Kohlschmidt N, Schroter B, et al: Linkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population and association studies in probands with neural tube defects (NTD). Am J Med Genet 1999;87:23–29.
112.
Swanson DA, Liu ML, Baker PJ, Garrett L, Stitzel M, et al: Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol 2001;21:1058–1065.
113.
Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, et al: Human methionine synthase. cDNA cloning, gene localization, and expression. J Biol Chem 1997;272:3628–3634.
114.
Gulati S, Brody LC, Banerjee R: Posttranscriptional regulation of mammalian methionine synthase by B12. Biochem Biophys Res Commun 1999;259:436–442.
115.
Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, et al: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867–1874.
116.
Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, et al: Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17:298–309.
117.
Paz MF, Avila S, Fraga MF, Pollan M, Capella G, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002;62:4519–4524.
118.
Burzynski M, Duriagin S, Mostowska M, Wudarski M, Chwalinska-Sadowska H, et al: MTR 2756 A>G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population. Lupus 2007;16:450–454.
119.
Kempisty B, Sikora J, Lianeri M, Szczepankiewicz A, Czerski P, et al: MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet 2007;17:177–181.
120.
Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, et al: Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 2002;71:1222–1226.
121.
Mostowska A, Hozyasz KK, Jagodzinski PP: Maternal MTR genotype contributes to the risk of non-syndromic cleft lip and palate in the Polish population. Clin Genet 2006;69:512–517.
122.
Blanton SH, Henry RR, Yuan Q, Mulliken JB, Stal S, et al: Folate pathway and nonsyndromic cleft lip and palate. Birth Defects Res A Clin Mol Teratol 2011;91:50–60.
123.
Bosco P, Gueant-Rodriguez RM, Anello G, Barone C, Namour F, et al: Methionine synthase (MTR) 2756 (A→G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, and elevated homocysteinemia are three risk factors for having a child with Down syndrome. Am J Med Genet A 2003;121:219–224.
124.
de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, et al: Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:3086–3096.
125.
Luka Z, Capdevila A, Mato JM, Wagner C: A glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme. Transgenic Res 2006;15:393–397.
126.
Nieman KM, Rowling MJ, Garrow TA, Schalinske KL: Modulation of methyl group metabolism by streptozotocin-induced diabetes and all-trans-retinoic acid. J Biol Chem 2004;279:45708–45712.
127.
Rowling MJ, Schalinske KL: Retinoic acid and glucocorticoid treatment induce hepatic glycine N-methyltransferase and lower plasma homocysteine concentrations in rats and rat hepatoma cells. J Nutr 2003;133:3392–3398.
128.
Beagle B, Yang TL, Hung J, Cogger EA, Moriarty DJ, et al: The glycine N-methyltransferase (GNMT) 1289 C→T variant influences plasma total homocysteine concentrations in young women after restricting folate intake. J Nutr 2005;135:2780–2785.
129.
Dinopoulos A, Matsubara Y, Kure S: Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 2005;86:61–69.
130.
Lamers Y, Williamson J, Gilbert LR, Stacpoole PW, Gregory JF 3rd: Glycine turnover and decarboxylation rate quantified in healthy men and women using primed, constant infusions of [1,2-13C2]glycine and [2H3]leucine. J Nutr 2007;137:2647–2652.
131.
Van Hove JL, Lazeyras F, Zeisel SH, Bottiglieri T, Hyland K, et al: One-methyl group metabolism in non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid homocysteine levels. J Inherit Metab Dis 1998;21:799–811.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.